



## **The European Innovation Council Fund Materializes its Support to Epigene Labs to Accelerate Precision Oncology R&D**

**PARIS, France, 30, November 2023** - Epigene Labs, an “AI-native biotech” company that creates solutions to accelerate precision oncology research and drug development, announces a significant investment from the European Innovation Council (EIC) Fund. While the detail of the investment remains confidential, it has been disclosed that long-standing investors of the company, including daphni, XAnge (Groupe Siparex), and Majycc Innovation Santé (UI Investissement), have also participated. This investment heralds outstanding technological and scientific strides made by Epigene Labs, which also received a multi-million grant last year as part of the EIC Accelerator program.

“The EIC Fund investment will help Epigene Labs accelerate precision oncology research and drug development, bringing better treatments to patients faster. The unique form of financing via the EIC - combining grants and equity - is proving itself highly attractive to Europe's most promising start-ups.” remarked Svetlana Georgieva, Chair of the EIC Fund Board.

Epigene Labs will strategically utilize this funding to expand its business team in Boston, United States, and to bring its innovative mCUBE platform to the industry's highest standards of data security and privacy.

The mCUBE platform exemplifies a groundbreaking approach to addressing formidable challenges in target identification, biomarker identification, and patient selection - often reducing traditional timelines from months to mere days. With aspirations to complete the development of mCUBE and establish a diverse portfolio of partnered and proprietary drug discovery programs in immuno-oncology by 2025, Epigene Labs is on a trajectory towards raising a Series A funding round. This investment from the EIC Fund, along with the contributions of its historical investors, marks a significant milestone towards this ambitious goal.

"This investment underscores the extraordinary progress of Epigene Labs in the realm of secondary analysis of multi-omic data for discovering and developing new precision therapies in oncology" said Akpeli Nordor, PharmD, PhD, Co-founder & CEO of Epigene Labs.

With its R&D headquarters in Paris and business headquarters in Boston, Epigene Labs has earned a strong track record of forming fruitful partnerships with world-class research institutes and biopharma companies.

Epigene Labs boasts a robust and scalable methodology to data integration, aiming to assimilate over 10,000 datasets by 2025. These meticulously curated datasets, encompassing four omics, fifty different cancer types, and forty clinical data elements, enable the company to assemble virtual research cohorts of unparalleled depth and breadth. The combination of

### **EPIGENE LABS SAS**

Adresse : 7, square Gabriel Fauré 75017 Paris, France

Téléphone : + 33 6 20 07 76 26 - Site web : [www.epigenelabs.com](http://www.epigenelabs.com)

Code NAF/APE : 6201Z - 845 367 713 R.C.S. Paris - Capital de 1.471,40 euros



these datasets into virtual research cohorts of unparalleled depth and breadth allows Epigene Labs, through mCUBE, to develop a first-in-class portfolio of immuno-oncology targets.

**About Epigene Labs:**

Epigene Labs is creating intelligence-augmenting solutions for precision oncology research and drug development. Designed by cancer scientists for cancer scientists, the company's mCUBE platform accelerates data-driven drug discovery, biomarker identification, and patient selection -- to bring better treatments to patients faster. Based in Paris and Boston, Epigene Labs was initially incubated at the Harvard Innovation Labs and launched in France with the support of prominent European investors. Epigene Labs has partnerships with world-class cancer research institutes and biopharmaceutical companies.

**About the European Innovation Council Fund:**

The European Innovation Council Fund from the European Commission is an agnostic Fund: it invests across all technologies and verticals, and all EU countries and countries associated to Horizon Europe. It provides the investment component of the EIC Accelerator blended finance.

The EIC Fund aims to fill a critical financing gap and its main purpose is to support companies in the development and commercialisation of disruptive technologies, bridging with and crowding in market players, and further sharing risk by building a large network of capital providers and strategic partners suitable for co-investments and follow-on funding.

The Fund pays particular attention to the empowerment and support of female founders as well as the ambition to reduce the innovation divide among EU countries.

**Contact:**

cecile@epigenelabs.com

**EPIGENE LABS SAS**

Adresse : 7, square Gabriel Fauré 75017 Paris, France

Téléphone : + 33 6 20 07 76 26 - Site web : [www.epigenelabs.com](http://www.epigenelabs.com)

Code NAF/APE : 6201Z - 845 367 713 R.C.S. Paris - Capital de 1.471,40 euros